Chronic Lymphocytic Leukemia New Reference: Obinutuzumab, ibrutinib, and venetoclax for Untreated CLL Ulas D. Bayraktar, MD 2023-09-23
Chronic Lymphocytic Leukemia New Reference: Ibrutinib and Rituximab for CLL Ulas D. Bayraktar, MD 2023-05-20
Chronic Lymphocytic Leukemia New Reference: Zanubrutinib for R/R CLL Ulas D. Bayraktar, MD 2023-01-10
